TAGI Pharma, Inc.: Excellence in Service – Providing Quality Products – Addressing Customers’ Unmet Needs
TAGI Pharma, Inc., a wholly owned subsidiary of Precision Dose, Inc., was established in 2010 as a specialty pharmaceutical company with the goal of penetrating the Retail Market Segment, taking advantage of the expanding generic opportunities in this Segment. Such opportunities are being driven by the transformation in care giving from the traditional settings of hospitals and physician offices to that of clinics, walk-in 24 hour medical facilities, and retail drug and food chains. Precision Dose, Inc., was established in 2003, and focuses on the Acute Care Markets, including Hospital and Institutional Segments with a line of unit dose liquid cups and oral syringes. With an established market presence, name recognition and a solid customer base, product portfolio expansion has evolved into new formats for delivering medications that continue to target our core customers, including our recent launch of blister packaged oral tablets and capsules, and a future line of injectable products currently in development.
TAGI Pharma is uniquely positioned in the marketplace, leveraging the Precision Dose relationships already established with the Hospital and Long Term Care customers, introducing products where there is demand in both the Retail and Institutional Market Segments. We also leverage Precision Dose’s warehouse and administrative infrastructure, which allows TAGI Pharma to focus on sales and marketing, product acquisition and development activities. TAGI Pharma has already established a network of quality-focused contract manufacturing organizations for its products and contract development organizations to support development activities. We are constantly seeking new partners and products, driving rapid and continuous growth of our product portfolio and pipeline.
TAGI Pharma’s strength is derived from our understanding of the market and identification of profitable product opportunities, coupled with an experienced Sales Organization that services the traditional generic customer, as well as making physician office visits promoting certain of our products. Our product quality and high service levels drive performance and ensure customer loyalty, and with an abundance of product opportunities through defined prospecting and selection strategies, we can ensure our product pipeline meets the needs of all stakeholders, particularly our customers. Currently our product portfolio consists of 16 product families with 26 SKU’s, and will continue to be expanded through licensing, acquisition and development initiatives – providing a product pipeline that consists of 17 products under active development.
Finally, in addition to myself, Mary Zieker (Vice President of Regulatory Affairs and Quality) and Kenny Harrington (Vice President of Sales and Marketing) oversee the direction of TAGI Pharma, and support the Company’s day-to-day activities. Our contact information can be found in the Partnership section and Contact Us section.
TAGI Pharma, Inc.